A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT05274997
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
YL-13027 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05228600
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05173805
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangzhou, China
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT05119933
- Locations
- 🇺🇸
The Tisch Cancer Institute Mount Sinai Health System Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Oncology Consultants, Houston, Texas, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
- Conditions
- Effectiveness，Safety，Thymic Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04975061
A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Phase 2
- Conditions
- PTCL
- Interventions
- Drug: YY-20394 treatment
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04705090
YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04500561
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT04379167
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT04370405
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Phase 1
Completed
- Conditions
- Lymphoplasmacytic LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaDiffuse Large B Cell LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT04279405
- Locations
- 🇨🇳
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath